EPIRUS Biopharma (EPRS) Misses Q4 EPS by 7c

EPIRUS Biopharma (NASDAQ: EPRS) reported Q4 EPS of ($0.63), $0.07 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $285 thousand versus the consensus estimate of $230 thousand.

Cash and cash equivalents and marketable securities, collectively "cash," totaled $31.5 million at December 31, 2015. The Company is in the process of evaluating various financing alternatives for operations, by raising additional capital through equity or debt financings or entering into collaboration agreements.

For earnings history and earnings-related data on EPIRUS Biopharma (EPRS) click here.

You May Also Be Interested In

• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• DeFi Development Corp. (DFDV) Misses Q2 EPS by 78c
• Reviva Pharmaceuticals Holdings, Inc. (RVPH) Tops Q2 EPS by 22c